MX2012000434A - Metodo de sanacion de herida y modulacion de cicatriz. - Google Patents

Metodo de sanacion de herida y modulacion de cicatriz.

Info

Publication number
MX2012000434A
MX2012000434A MX2012000434A MX2012000434A MX2012000434A MX 2012000434 A MX2012000434 A MX 2012000434A MX 2012000434 A MX2012000434 A MX 2012000434A MX 2012000434 A MX2012000434 A MX 2012000434A MX 2012000434 A MX2012000434 A MX 2012000434A
Authority
MX
Mexico
Prior art keywords
wound healing
scar
modulation
corticosteroids
administration
Prior art date
Application number
MX2012000434A
Other languages
English (en)
Spanish (es)
Inventor
Brian C Keller
Original Assignee
Crescendo Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crescendo Therapeutics Llc filed Critical Crescendo Therapeutics Llc
Publication of MX2012000434A publication Critical patent/MX2012000434A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2012000434A 2009-07-09 2010-07-09 Metodo de sanacion de herida y modulacion de cicatriz. MX2012000434A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22440809P 2009-07-09 2009-07-09
US22621609P 2009-07-16 2009-07-16
PCT/US2010/041576 WO2011006100A1 (en) 2009-07-09 2010-07-09 Method of wound healing and scar modulation

Publications (1)

Publication Number Publication Date
MX2012000434A true MX2012000434A (es) 2012-04-11

Family

ID=43427950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000434A MX2012000434A (es) 2009-07-09 2010-07-09 Metodo de sanacion de herida y modulacion de cicatriz.

Country Status (10)

Country Link
US (1) US20110009374A1 (enExample)
EP (1) EP2451280A4 (enExample)
JP (1) JP2012532889A (enExample)
CN (1) CN102480969A (enExample)
AR (1) AR077410A1 (enExample)
AU (1) AU2010271205A1 (enExample)
BR (1) BR112012001098A2 (enExample)
CA (1) CA2767661A1 (enExample)
MX (1) MX2012000434A (enExample)
WO (1) WO2011006100A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100322875A1 (en) 2009-06-18 2010-12-23 Advanced Bio-Technologies, Inc. Silicone scar treatment preparation
US8623040B2 (en) 2009-07-01 2014-01-07 Alcon Research, Ltd. Phacoemulsification hook tip
WO2012012390A1 (en) 2010-07-19 2012-01-26 Marvphyt Development Llc Botanical composition and methods of manufacture and use
US10258505B2 (en) 2010-09-17 2019-04-16 Alcon Research, Ltd. Balanced phacoemulsification tip
ITMI20111050A1 (it) * 2011-06-10 2012-12-11 Sevecom Spa Uso di emulsionanti in associazione con oleine vegetali in un alimento per animali.
CN103648483A (zh) 2011-06-24 2014-03-19 莫茨制药有限及两合公司 包含洋葱提取物和脂质体的组合物
US9364510B2 (en) 2011-07-19 2016-06-14 Marvphyt Development Llc Botanical composition and methods of manufacture and use
EP2736887B1 (en) 2011-07-29 2017-10-18 Karyopharm Therapeutics, Inc. Hydrazide containing nuclear transport modulators and uses thereof
MX369385B (es) * 2011-09-13 2019-11-07 Univ Brigham Young Productos para cicatrizar heridas tisulares.
US9474685B2 (en) 2011-09-28 2016-10-25 Sure-Shot Medical Device Inc. Apparatus for localized dermatological treatment
GB201120724D0 (en) * 2011-12-01 2012-01-11 Gauthier Rene System and method for alleviating the appearance of scars and/or scar tissue
FR2985064B1 (fr) * 2011-12-23 2016-02-26 Oreal Procede pour delivrer un conseil cosmetique
WO2013162723A1 (en) * 2012-04-27 2013-10-31 Dow Corning Corporation Topical formulation compositions containing silicone based excipients to deliver actives to a substrate
IN2014DN09434A (enExample) 2012-05-09 2015-07-17 Karyopharm Therapeutics Inc
US11458199B2 (en) * 2012-08-21 2022-10-04 Opko Pharmaceuticals, Llc Liposome formulations
US9808654B2 (en) * 2013-02-11 2017-11-07 Jan Marini Skin Research Post procedure skin care gel and methods of use thereof
WO2014144772A1 (en) * 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
CN105122261B (zh) * 2013-04-23 2020-04-24 惠普发展公司，有限责任合伙企业 从遭到破坏的系统启动代码中恢复的方法以及计算装置
CN110386919B (zh) 2013-06-21 2023-07-14 卡尔约药物治疗公司 核转运调节剂及其用途
US11432990B2 (en) 2013-08-30 2022-09-06 ISOS Solutions, LLC Textured apparatus with therapeutic material incorporated therein and methods of manufacturing same
US9226890B1 (en) 2013-12-10 2016-01-05 Englewood Lab, Llc Polysilicone base for scar treatment
CN105793829B (zh) * 2013-12-23 2020-01-21 英特尔公司 用于集成组件互连的装置、方法和系统
US11266685B2 (en) 2014-06-09 2022-03-08 Klox Technologies Inc. Silicone-based biophotonic compositions and uses thereof
MA40433A (fr) 2014-07-21 2017-06-14 Sevecom Spa Émulsion en poudre pour aliments pour animaux
CN111484483B (zh) 2014-08-15 2023-05-26 卡尔约药物治疗公司 赛灵克斯的多晶型物
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
AU2018215678A1 (en) 2017-02-06 2019-08-22 Board Of Regents Of The University Of Texas System Compositions and methods of modulating short-chain dehydrogenase activity
EP3856155A4 (en) * 2018-09-28 2022-10-05 Joel Studin DELIVERY OF STEROIDS AND LARGE MOLECULES THROUGH THE PORE
IL321451A (en) 2018-11-21 2025-08-01 Univ Case Western Reserve Compositions and methods of modulating short-chain dehydrogenase activity
US20200397720A1 (en) * 2019-06-23 2020-12-24 Charles Huntington Gallina Method and formulation for treatment of wounds by new tissue regeneration with reduced trauma and scar tissue formation
CN110368498A (zh) * 2019-08-26 2019-10-25 瑞希(重庆)生物科技有限公司 一种促进伤口愈合的制剂及其制备方法
MX2022010258A (es) 2020-02-21 2023-01-24 Univ Case Western Reserve Composiciones y métodos para tratar la lesión renal.
WO2024026045A2 (en) * 2022-07-27 2024-02-01 Bio Med Sciences, Inc. Method of improving outcomes of dermal tattoos and tattoo removal procedures

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337076B1 (en) * 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
KR100362924B1 (ko) * 2000-01-11 2002-11-30 주식회사 동구약품 외피용약제 조성물
WO2001089464A1 (en) * 2000-05-23 2001-11-29 Unilever Plc Deodorant and/or antiperspirant compositions
GB0018466D0 (en) * 2000-07-27 2000-09-13 Strakan Pharm Ltd Keloid Treatment
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US6998421B2 (en) * 2001-06-07 2006-02-14 Biozone Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase - 2
US6495596B1 (en) * 2001-03-23 2002-12-17 Biozibe Laboratories, Inc. Compounds and methods for inhibition of phospholipase A2 and cyclooxygenase-2
JP4450545B2 (ja) * 2001-07-05 2010-04-14 ロート製薬株式会社 エアゾール製剤
JP4549006B2 (ja) * 2002-05-07 2010-09-22 ロート製薬株式会社 ゲル軟膏
GB0216427D0 (en) * 2002-07-16 2002-08-21 Advanced Biotechnologies Inter Wound dressing
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
JP2008502647A (ja) * 2004-06-17 2008-01-31 ガルデルマ・ソシエテ・アノニム シリコーン剤、コルチコステロイドおよびビタミンｄまたはその誘導体を含む乾癬治療用組成物
JP2008542423A (ja) * 2005-06-10 2008-11-27 ガルデルマ・ソシエテ・アノニム 皮膚を通しての薬物の制御放出方法
MX2009009557A (es) * 2007-03-08 2010-08-10 Crescendo Therapeutics Llc Formulaciones de aposito para prevenir o reducir la cicatrizacion.
US20080317830A1 (en) * 2007-06-25 2008-12-25 Liolabs Llc Compositions and Methods for the Treatment of Wounds and Scar Tissue
DE102009030931A1 (de) * 2009-06-24 2010-12-30 Eberhard-Karls-Universität Tübingen Universitätsklinikum Chirurgisches Wundverschlusselement

Also Published As

Publication number Publication date
EP2451280A4 (en) 2012-12-26
AR077410A1 (es) 2011-08-24
AU2010271205A1 (en) 2012-02-09
EP2451280A1 (en) 2012-05-16
CA2767661A1 (en) 2011-01-13
US20110009374A1 (en) 2011-01-13
BR112012001098A2 (pt) 2015-09-01
WO2011006100A1 (en) 2011-01-13
CN102480969A (zh) 2012-05-30
JP2012532889A (ja) 2012-12-20

Similar Documents

Publication Publication Date Title
WO2011130302A3 (en) Method of treating obesity using antioxidant inflammation modulators
PH12017500864A1 (en) Anti-notch1 antibodies
IN2012DN03883A (enExample)
MX2011007930A (es) Conjugados de insulina cristalina.
CA2871471C (en) Dna-pk inhibitors
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
IN2012DN02081A (enExample)
WO2012125544A3 (en) Necroptosis inhibitors and methods of use therefor
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
UA105487C2 (uk) Заміщені дигідропіразолони як інгібітори hif-проліл-4-гідроксилази
EP4414376A3 (en) Novel depsipeptide and uses thereof
PH12015502405B1 (en) Methods and compositions for wound healing
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
WO2013006335A3 (en) Methods and compositions useful for treating fitzpatrick type iv, v or vi skin
MX2011009277A (es) Composicion de leucocito activada.
MX339361B (es) Derivados de alternano.
IN2014DN03010A (enExample)
WO2011136513A3 (ko) 디히드록시벤조산 유도체를 포함하는 골이식용 또는 골충진용 조성물
MX337070B (es) Método para preparar un conjugado klh-egfrviii.
WO2012082942A3 (en) Neuropeptide analogs, compositions, and methods for treating pain
WO2011116351A3 (en) Methods and compositions for the treatment of cancer
WO2011044587A3 (en) Cytoprotective or therapeutic plant composition
MX2011007384A (es) Terapias de combinacion para trastornos neoplásticos.
WO2015050686A3 (en) Methods and compositions to inhibit metastasis and to treat fibrosis and to enhance wound healing

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ABBVIE INC.

FA Abandonment or withdrawal